STAT5B leukemic mutations, altering SH2 tyrosine 665, have opposing impacts on immune gene programs

Hye Kyung Lee,Jichun Chen,Rachael L. Philips,Sung-Gwon Lee,Xingmin Feng,Zhijie Wu,Chengyu Liu,Aaron B. Schultz,Molly Dalzell,Foster Birnbaum,Joel A. Sexton,Amy E. Keating,John J. O'Shea,Neal S. Young,Alejandro V. Villarino,Priscilla A. Furth,Lothar Hennighausen

DOI: https://doi.org/10.1101/2024.12.20.629685

2024-12-22

Abstract:STAT5B is a vital transcription factor for lymphocytes. Here, function of two STAT5B mutations from human T cell leukemias: one substituting tyrosine 665 with phenylalanine (STAT5BY665F), the other with histidine (STAT5BY665H) was interrogated. In silico modeling predicted divergent energetic effects on homodimerization with a range of pathogenicity. In primary T cells in vitro STAT5BY665F showed gain-of-function while STAT5BY665H demonstrated loss-of-function. Introducing the mutation into the mouse genome illustrated that the gain-of-function Stat5bY665F mutation resulted in accumulation of CD8+ effector and memory and CD4+ regulatory T-cells, altering CD8+/CD4+ ratios. In contrast, STAT5BY665H knock-in mice showed diminished CD8+ effector and memory and CD4+ regulatory T cells. In contrast to wild-type STAT5, the STAT5BY665F variant displayed greater STAT5 phosphorylation, DNA binding and transcriptional activity following cytokine activation while the STAT5BY665H variant resembled a null. The work exemplifies how joining in silico and in vivo studies of single nucleotides deepens our understanding of disease-associated variants, revealing structural determinants of altered function, defining mechanistic roles, and, specifically here, identifying a gain-of function variant that does not directly induce hematopoietic malignancy.

Biology